Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics
F Misawa, T Kishimoto, K Hagi, JM Kane… - Schizophrenia …, 2016 - Elsevier
Objective We aimed to assess whether long-acting injectable antipsychotics (LAIs), which
are initiated in a loading strategy or overlapping with oral antipsychotics (OAPs) and which …
are initiated in a loading strategy or overlapping with oral antipsychotics (OAPs) and which …
Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review
I Pacchiarotti, J Tiihonen, GD Kotzalidis… - European …, 2019 - Elsevier
Abstract Long-Acting Injectable Antipsychotics (LAIs) are used to overcome non-compliance
in psychoses, mainly schizophrenia spectrum disorders. We aimed to summarize available …
in psychoses, mainly schizophrenia spectrum disorders. We aimed to summarize available …
[图书][B] The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia
American Psychiatric Association - 2020 - books.google.com
The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …
Schizophrenia seeks to reduce these substantial psychosocial and public health …
Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics
S Heres, M Lambert, R Vauth - European Psychiatry, 2014 - cambridge.org
The use of long-acting injectable antipsychotics (LAIs) in schizophrenia is usually restricted
to patients in long-term treatment, who prefer them to oral antipsychotics, and to patients with …
to patients in long-term treatment, who prefer them to oral antipsychotics, and to patients with …
Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly
E Biagi, E Capuzzi, F Colmegna, A Mascarini… - Advances in …, 2017 - Springer
Introduction Prevention of relapse is a major challenge in schizophrenia, a disease
characterized by poor adherence to antipsychotic medication leading to multiple …
characterized by poor adherence to antipsychotic medication leading to multiple …
Barriers to the use of three-month paliperidone palmitate formulation: a study from an Italian real-world setting
G Cirnigliaro, V Battini, R Cafaro, G Mosini… - Expert Review of …, 2023 - Taylor & Francis
Background Long-acting injectable paliperidone can improve adherence in psychotic
patients and reduce relapses and healthcare resource utilization (HRU). This study …
patients and reduce relapses and healthcare resource utilization (HRU). This study …
Shared decision making PLUS–a cluster-randomized trial with inpatients suffering from schizophrenia (SDM-PLUS)
J Hamann, F Holzhüter, L Stecher, S Heres - BMC psychiatry, 2017 - Springer
Background Shared decision making (SDM) is a model of how doctors and patients interact
with each other. It aims at changing the traditional power asymmetry between doctors and …
with each other. It aims at changing the traditional power asymmetry between doctors and …
Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States
Background No research to date has examined antipsychotic (AP) use, healthcare resource
use (HRU), costs, and quality of care among those with schizophrenia in the Medicare …
use (HRU), costs, and quality of care among those with schizophrenia in the Medicare …
Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable …
Definition of an appropriate and personalized treatment plan focused on long-term
outcomes is crucial in the management of schizophrenia. Following review of the literature, a …
outcomes is crucial in the management of schizophrenia. Following review of the literature, a …
Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics
CH Lin, HY Chan, CC Hsu, FC Chen - Journal of Affective Disorders, 2021 - Elsevier
Objective This study aimed to analyze time to rehospitalization in patients with bipolar mania
discharged on long-acting injectable antipsychotics (LAIs) or oral antipsychotics (OAPs) …
discharged on long-acting injectable antipsychotics (LAIs) or oral antipsychotics (OAPs) …